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Abstract 
Review on t(11;11)(q14;q23) and inv(11)(q14q23) 
KMT2A/PICALM, with data on clinics and the 
genes involved. 
KEYWORDS 
Chromosome 11; KMT2A; PICALM; acute myeloid 
leukemia; acute lymphoblastic leukemia. 
Clinics and pathology 
Disease 
Acute myeloid leukemia (AML) and acute 
lymphoblastic leukemia (ALL). 
Clinics 
There was the case of a 12-week-old female infant 
with acute monocytic leukemia (M5b) and 
inv(11)(q14q23), dead at day 11 (Wechsler et al., 
2003). 
Otherwise, in a large study of cases of chromosomal 
rearrangements involving the human KMT2A 
(MLL) gene, a t(11;11)(q14;q23) or inv(11)(q14q23) 
KMT2A/PICALM was found in 1 out of 440 infant 
ALL patients, 1 out of 105 infant AML patients, 1 
out of 205 pediatric ALL patients, 1 out of 272 adult 
AML patients, and none in 202 pediatric AML 
patients, nor in 333 adult ALL patients (Meyer et al., 
2013). Note: the case by Meyer et al., 2006 was 
reused in Meyer et al., 2013. 
Genes involved and 
proteins 
PICALM (clathrin assembly lymphoid 
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PICALM codes for a 652-aa protein, and shorter 
isoforms. It is an endocytosis adaptor, in the initial 
stages of coated pit invagination together with 
clathrin, AP2 (adaptor related protein complex 
subunits) and PtdIns(4,5)P2 (phosphatidylinositol-
4,5- bisphosphate) containing membranes. PICALM 
interacts with CLTC (clathrin heavy chain) 
promoting assembly of clathrin triskelia into clathrin 
cages. Clathrin is the major binding partner of 
PICALM (Archangelo et al., 2006). PICALM is 
required for erythroid maturation and transferrin 
internalization.  
 
 PICALM domains:  PICALM contains an AP180 
N-terminal homology (ANTH) domain (or ENTH 
domain for epsin NH2-terminal domain)) (note: 
"AP180" is SNAP91, and epsin is EPN1, EPN2 or 
EPN3) and an assembly domain (AD). ANTH: 
amino acids (aa) 1-289; AD: aa 290-652.  
 
ANTH: The ANTH domain is folded; it binds 
phosphatidylinositol-4,5- bisphosphate 
(PtdIns(4,5)P2) via a lysine-rich motif, and vesicle 
associated membrane proteins (VAMPs). There are 
nine alpha helices forming a solenoid (aa 20-30, 40-
50, 56-67, 71-90, 91-100, 115-142, 160-180, 191-
222, 225-258). In addition, there are PtdIns(4,5)P2-
binding residues at aa 28, 38, 40, 41 (K, K, K, H).  
 
AD: The AD has two subdomains: a central clathrin 
and adaptor protein binding (CLAP) domain and the 
remainder is an unnamed domain (ADΔCLAP). 
CLAP domain: aa 290-525, with CLAP motifs: DIF, 
DLL, DPF (see below), and FESVF: aa 488-493. 
Unnamed domain (ADΔCLAP): aa 526-652. 
ADΔCLAP is basic. The assembly domain (AD) has 
a role of clathrin and AP2 binding.  
 
 Other domains:  transcriptional activation domain 
(TAD) (aa 408-572). PICALM is O-GlcNAc 
modified at aa 454 (S). Nuclear export signal (NES) 
LANLVGNLGI: aa 544-553. The NES consensus 
sequence is ΦX1-3ΦX2-3ΦXΦ, where Φ is most 
often leucine. The NES is the factor which 
contributes to PICALM/MLLT10 mediated 
leukemogenesis.  
 
 Protein interaction domains:  PICALM binds 
directly to various vesicle associated membrane 
proteins: VAMP2 , VAMP3, VAMP4, VAMP7 and 
VAMP8. PIMREG (FAM64) interaction domain: aa 
221-294; FHL2 interaction domain: aa 294-335; 
proteins with an EPS15 homology domain 
interaction domain: NPF (Asp-Pro-Phe) motif (aa 
437-439). Clathrin binding motifs (CBM): Binding 
of clathrin heavy chain (CLTC) involves primarily 
aa 413-652, however, the entire AD is required for 
efficient clathrin binding. PICALM has one DLL 
(Asp-Leu-Leu) motif (aa 392-394); one DIF (Asp-
Ile-Phe) motif (aa 375-377) which could bind 
clathrin, but also AP2A1 (AP2 alpha subunit); and 
one DPF (Asp-Pro-Phe) sequence (aa 420-422), 
which can also bind AP2A1. Other clathrin binding 
sequences involve L/I (Leu/Ile) in aa 540-553 and aa 
649-652 (Tebar et al., 1999; Ford et al., 2001; 
Archangelo et al., 2006; Pašaliç et al., 2011; 
Moshkanbaryans et al., 2014; Moshkanbaryans et 
al., 2016). 
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37 exons, spanning about 120 kb; 13-15 mRNA 
Protein 
3969 amino acids, 431 kDa; Transcriptional 
regulatory factor. MLL is known to be associated 
with more than 30 proteins, including the core 
components of the SWI/SNF chromatin remodeling 
complex and the transcription complex TFIID. MLL 
binds promotors of HOX genes through acetylation 
and methylation of histones. MLL is a major 
regulator of hematopoesis and embryonic 
development, through regulation of HOX genes 
expression regulation (HOXA9 in particular). 




The KMT2A breakpoint was in intron 9 in 2 cases, 
and in intron 10 in the 2 other cases (Meyer et al., 
2013). The full-length KMT2A/PICALM transcript 
was 5409 bp long, including 4218 bp from KMT2A 
exons 1-7 and 1191 bp from PICALM (exons 8-20) 
in Wechsler et al., 2003. 
Fusion protein 
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The KMT2A/PICALM fusion protein was contained 
1803 amino acids and included 1406  
amino acids from KMT2A A-T hooks and repression 
domain, and a PICALM-derived clathrin-binding 
domain in Wechsler et al., 2003. 
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